{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:17:57Z","timestamp":1782494277023,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.amjmed.2011.08.026","type":"journal-article","created":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T17:15:27Z","timestamp":1332436527000},"page":"381-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome"],"prefix":"10.1016","volume":"125","author":[{"given":"Eric","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2011.08.026_bib1","first-page":"1910","article-title":"The epidemiology of irritable bowel syndrome in North America: a systematic review","volume":"97","author":"Saito","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.gtc.2005.02.011","article-title":"Definition and classification of irritable bowel syndrome: current consensus and controversies","volume":"34","author":"Longstreth","year":"2005","journal-title":"Gastroenterol Clin N"},{"key":"10.1016\/j.amjmed.2011.08.026_bib3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2036.2007.03422.x","article-title":"Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III","volume":"26","author":"Ersryd","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.08.026_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004836-199407000-00008","article-title":"An office guide to whole-gut transit time","volume":"19","author":"Heaton","year":"1994","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2011.08.026_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/gut.51.suppl_1.i67","article-title":"Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome","volume":"51","author":"Delvaux","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.amjmed.2011.08.026_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MED.0b013e32831e9c8e","article-title":"Serotonin in the gastrointestinal tract","volume":"16","author":"Camilleri","year":"2009","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.amjmed.2011.08.026_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.dld.2009.07.023","article-title":"The putative role of the intestinal microbiota in irritable bowel syndrome","volume":"41","author":"Collins","year":"2009","journal-title":"Digest Liver Dis"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2011.08.026_bib9","first-page":"S1","article-title":"An evidence-based position statement on the management of irritable bowel syndrome","volume":"104","author":"Brandt","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib10","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT 3 antagonists and 5-HT 4 agonists in irritable bowel syndrome: systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/gut.2008.163162","article-title":"Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis","volume":"58","author":"Ford","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.amjmed.2011.08.026_bib12","first-page":"A54","article-title":"Efficacy of rifaximin in patients with irritable bowel syndrome: a meta analysis","volume":"215","author":"Menees","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2011.08.026_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2011.02.030","article-title":"Questioning the bacterial overgrowth hypothesis of IBS: an epidemiologic and evolutionary perspective","author":"Spiegel","year":"2011","journal-title":"Clin Gastroenterol H"},{"key":"10.1016\/j.amjmed.2011.08.026_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2011.08.026_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.amjmed.2011.08.026_bib16","series-title":"Utilizing Existing Databases","first-page":"220","article-title":"Designing Clinical Research","author":"Hulley","year":"2007"},{"key":"10.1016\/j.amjmed.2011.08.026_bib17","first-page":"1351","article-title":"What to add to nothing?","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.amjmed.2011.08.026_bib18","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analysis of controlled clinical trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.amjmed.2011.08.026_bib19","first-page":"201","article-title":"Wirksamkeit und vertraglichkeit eines antidepressivuns beim colon irritabile","volume":"38","author":"Boerner","year":"1988","journal-title":"Therapiewoche"},{"key":"10.1016\/j.amjmed.2011.08.026_bib20","first-page":"1621","article-title":"Die therapie des colon irritabile mit trimipramin (Herphonal) - Eine kontrollierte studie","volume":"46","author":"Bergmann","year":"1991","journal-title":"Z Klin Med"},{"key":"10.1016\/j.amjmed.2011.08.026_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0016-5085(03)00669-3","article-title":"Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders","volume":"125","author":"Drossman","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2011.08.026_bib22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0033-3182(78)70930-8","article-title":"Irritable colon and depression","volume":"19","author":"Heefner","year":"1978","journal-title":"Psychosomatics"},{"key":"10.1016\/j.amjmed.2011.08.026_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/00365528209181108","article-title":"The effect of trimipramine in patients with the irritable bowel syndrome: a double-blind study","volume":"17","author":"Myren","year":"1982","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib24","first-page":"1041","article-title":"Different therapeutic regimens in irritable bowel syndrome","volume":"32","author":"Nigam","year":"1984","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.amjmed.2011.08.026_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10620-007-9830-4","article-title":"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial","volume":"53","author":"Talley","year":"2008","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.amjmed.2011.08.026_bib26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2036.2008.03633.x","article-title":"Clinical trial: the effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome","volume":"27","author":"Vahedi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.08.026_bib27","first-page":"243","article-title":"Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients","volume":"33","author":"Vij","year":"1991","journal-title":"Indian J Psychiatry"},{"key":"10.1016\/j.amjmed.2011.08.026_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.2000.00684.x","article-title":"A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome","volume":"14","author":"Bardhan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.08.026_bib29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","article-title":"Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist","volume":"13","author":"Camilleri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.08.026_bib30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2011.08.026_bib31","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome","volume":"161","author":"Camilleri","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2011.08.026_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1572-0241.2005.40365.x","article-title":"A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS","volume":"100","author":"Chang","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib33","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1572-0241.2007.01282.x","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS","volume":"102","author":"Krause","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib34","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1572-0241.2004.30509.x","article-title":"Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome","volume":"99","author":"Chey","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib35","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","article-title":"Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome","volume":"96","author":"Lembo","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2011.08.026_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.08.026_bib39","doi-asserted-by":"crossref","first-page":"A545","DOI":"10.1016\/S0016-5085(08)62544-5","article-title":"Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response","volume":"134","author":"Lembo","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2011.08.026_bib40","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2004.04127.x","article-title":"Paroxetine to treat irritable bowel syndrome not responding to high fiber diet: a double-blind placebo-controlled trial","volume":"99","author":"Tabas","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib41","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/gut.2005.077503","article-title":"A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome","volume":"55","author":"Tack","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.amjmed.2011.08.026_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2036.2005.02566.x","article-title":"The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized controlled study","volume":"22","author":"Vahedi","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.08.026_bib43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1542-3565(03)70039-1","article-title":"The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double-blind, randomized, placebo-controlled study","volume":"1","author":"Kuiken","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.amjmed.2011.08.026_bib44","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","article-title":"Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation","volume":"27","author":"Johanson","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.08.026_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome\u2014results of two randomized placebo-controlled studies","volume":"29","author":"Drossman","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2011.08.026_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gtc.2010.12.013","article-title":"The effect of irritable bowel syndrome on health-related quality of life and health care expenditure","volume":"40","author":"Agarwal","year":"2011","journal-title":"Gastroenterol Clin North Am"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934311007923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934311007923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:57:19Z","timestamp":1757581039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934311007923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0002934311007923"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2011.08.026","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2011.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}